Drugs / Cirtuvivint
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06856499 | Dec 2025 → Jul 2027 expected | fallopian tube cancer, ovarian endometrial cancer, primary peritoneal carcinoma | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 1 | NCT06484062 | Aug 2025 → Jun 2028 expected | acute myeloid leukemia, myelodysplastic syndrome | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07155200 | Dec 2025 → Jul 2028 expected | small cell lung carcinoma | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07032285 | Jan 2025 → Apr 2027 expected | soft tissue sarcoma | Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cirtuvivint | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07155200 ↗ |
| Known as | SM08502 | “Cirtuvivint (SM08502) is a first in class pan CDC-like kinase (CLK) and dual specificity tyrosine kinase (DYRK) inhibitor with suspected multiple anti-tumor mechanisms of...” NCT06856499 ↗1“Cirtuvivint (SM08502) will be administered orally at 80 mg/day, 5 days on/2 days off.” NCT07032285 ↗ |
| Action | Inhibit | “Cirtuvivint may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.” NCT06484062 ↗ |
| Modality | Small molecule | “Cirtuvivint is a small molecule inhibitor” NCT07155200 ↗ |
| Route | Oral | “Patients receive cirtuvivint orally (PO)” NCT06484062 ↗ |